Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
Date:6/8/2009

s study are being treated at the NCI and at top cancer centers throughout the United States. The NCI is serving as coordinating center for the study, which includes the initiation and training of the new clinical trial centers for this important trial. Plans under the CRADA include continuing patient enrollments and completing the clinical testing of PHP as treatment for a number of life threatening liver diseases.

The Phase III Study

The Phase III study is testing Delcath's PHP(TM) System for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath System is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.

Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's b
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Cynosure, Inc. (Nasdaq: CYNO ... treatment systems for high-volume applications, today reported financial results ... 2014 financial results incorporate the acquisition of Palomar Medical ... Second-Quarter 2014 Financial Highlights ... , Non-GAAP net income of $7.1 million, or ...
(Date:7/29/2014)... VIENNA , July 29, 2014 ... Vienna, Austria will present data from a ... that aims to slow or stop Parkinson,s disease progression. ... a $ 1.5 million grant and will discuss the impact ... community. When:   Thursday, July 31, 2014 ...
(Date:7/29/2014)... July 29, 2014  Drug development for hepatitis ... incidence rates and the intense need for curative ... Change is underway as the market moves away ... effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first of ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... , FORT WORTH, Texas, Dec. 16 ... rapidly growing provider of specialty medical products, announced today that ... its patented orthopedic bone void fillers. The company currently ... bio-products market, estimated to be a multi-billion dollar international market. ...
... , CHICAGO, Dec. 16 A new ... clinical review of specialty pharmaceuticals has increased health plan staff ... , AIM, a leading diagnostic imaging benefit management and technology ... and an operating subsidiary of WellPoint, Inc. (NYSE: ...
Cached Medicine Technology:Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 2Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4
(Date:7/29/2014)... For survivors of severe combat injuries threatening more than ... a good record of safety and effectiveness in avoiding ... Plastic and Reconstructive Surgery , the ... Plastic Surgeons (ASPS). , Experience with multiple limb ... shows good success rates, with no increase in complications ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Chlorine helps keep ... more likely to develop eye infections, doctors say. ... as well as blurry vision, said Dr. Sampson Davis, ... in New Jersey. It,s important to understand why ... washes away the outer film layer of the eye ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 According to ... of Time Magazine titled “From Kim’s Butt to Angelina’s ... Kardashian’s butt is the celebrity feature most requested ... features include Beyoncé’s butt, Jennifer Lawrence’s nose, ... information is based on data collected by an online ...
(Date:7/29/2014)... Hudson County, NJ (PRWEB) July 29, 2014 ... that two leading pediatricians have joined our network, ... Regina Politis and Dr. Sushma Kaki. Hundreds of ... Medical Group, a comprehensive network of top doctors ... range of specialties. This latest acquisition represents CarePoint ...
(Date:7/29/2014)... D.C. (PRWEB) July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. , The ...
Breaking Medicine News(10 mins):Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2Health News:Protect Your Eyes When Hitting the Pool 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... NEW YORK, Dec. 6 Informed Medical Communications ... the,bio-pharmaceutical industry, today announced the sale of its ... WA, HealthTalk is a,leading online source of chronic ... audience among patients and caregivers. The,announcement was made ...
... EDITOR,S PICK: Anticancer drugs might be of benefit to ... an inherited blood disorder caused by a genetic mutation ... of the beta-globin chain of hemoglobin (Hb). Red blood ... shape upon deoxygenation and this causes them to get ...
... Videos Created by Hospitals from Around the Country Appeal to the ... First-Ever Contest to Win a Free MRI, MALVERN, Pa., Dec. ... their community, but can,t seem to find the time,now,s your chance ... just,one click of your mouse! The video posting period in Siemens ...
... Dec. 6 /PRNewswire-FirstCall/ - Neurochem,(International) Limited (Neurochem), a ... TSX: NRM), announces that the Company has received ... Administration (FDA),that Neurochem,s response to the July 2007 ... eprodisate (KIACTA(TM)) for the treatment of,Amyloid A (AA) ...
... Today, the American,Medical Women,s Association (AMWA) announced that ... discuss his plan for health care reform,with thousands ... the,country on December 7., "As women and ... issue of health care is to our country ...
... by St. Jude Childrens Research Hospital scientists offers new ... excess proteins and could lead to new cancer treatments. ... carry out protein disposal, a finding that helps to ... this process. The discovery is important because the newly ...
Cached Medicine News:Health News:Informed Medical Communications Sells Consumer Internet Division to Revolution Health 2Health News:JCI online early table of contents: Dec. 6, 2007 2Health News:JCI online early table of contents: Dec. 6, 2007 3Health News:JCI online early table of contents: Dec. 6, 2007 4Health News:JCI online early table of contents: Dec. 6, 2007 5Health News:JCI online early table of contents: Dec. 6, 2007 6Health News:JCI online early table of contents: Dec. 6, 2007 7Health News:JCI online early table of contents: Dec. 6, 2007 8Health News:JCI online early table of contents: Dec. 6, 2007 9Health News:The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens' Newest MRI Technology 2Health News:The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens' Newest MRI Technology 3Health News:Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review 2Health News:Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review 3Health News:AMWA Hosts Health Care Conversation With Congressman Kucinich 2Health News:St. Jude finds mechanism for faulty protein disposal 2Health News:St. Jude finds mechanism for faulty protein disposal 3Health News:St. Jude finds mechanism for faulty protein disposal 4
... is an innovative and efficient inverted ... complements any research facility. Improved mechanics ... offers the TS100 binocular and TS100-F ... comes with a photo port that ...
... imaging camera system designed for scientific ... megapixel digital cameras provides high-resolution, full-color ... on a PC via its Firewire ... previewing capability is accompanied by automatic ...
... color imaging camera system designed for ... performance, megapixel digital cameras provides high-resolution, ... them on a PC via its ... "live" previewing capability is accompanied by ...
... premium photomicrography system that greatly simply ... most difficult specimens. Designed with real life ... solution to the complex problem of fluorescence ... control, the system utilizes special programs designed ...
Medicine Products: